Stockholm - Delayed Quote SEK

Spago Nanomedical AB (publ) (SPAGO.ST)

0.2170

-0.0010

(-0.46%)

At close: April 16 at 1:33:40 PM GMT+2

Notice To Annual General Meeting of Spago Nanomedical AB (PUBL)

LUND, SE / ACCESS Newswire / April 9, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) This English version of the notice to the Annual General Meeting is for convenience only. The Swedish version prevails in the event of any inconsistency. The ...

ACCESS Newswire 7 days ago

SPAGO.ST
-0.46%
7UX.F
Nomination Committee's Proposal for a New Chairman and Composition of Spago Nanomedical’s Board

LUND, SE / ACCESS Newswire / March 20, 2025 /Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company's nomination committee proposes a changed board composition to meet the needs of the company's current ...

ACCESS Newswire 27 days ago

7UX.F

SPAGO.ST
-0.46%
Spago Nanomedical Proceeds with Increased Dose in the Phase I/IIa study Tumorad-01

LUND, SE / ACCESSWIRE / March 04, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) recommends a dose increase in the ongoing phase I/IIa study Tumorad-01 ...

ACCESS Newswire last month

SPAGO.ST
-0.46%
7UX.F
Spago Nanomedical year-end report January-December, 2024

Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) OCTOBER - DECEMBER IN BRIEF Net sales for the quarter amounted to KSEK 617 (KSEK 731) The loss for the quarter amounted to KSEK -7,830 (KSEK -9,417) Operating expenses for the quarter amounted to KSEK -10,223 ...

ACCESS Newswire 2 months ago

SPAGO.ST
-0.46%
7UX.F
Spago Nanomedical Article on SPAGOPIX-01 Clinical Results Accepted for Publication in Investigative Radiology

LUND, SWEDEN / ACCESSWIRE / January 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that a manuscript on product candidate pegfosimer manganese has been accepted for publication in the highly regarded ...

ACCESS Newswire 2 months ago

SPAGO.ST
-0.46%
7UX.F
Second Patient Group Successfully Dosed in Spago Nanomedical's Phase I/IIa Study Tumorad-01

LUND, SE / ACCESSWIRE / December 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that all patients in the second patient group have been dosed according to plan in the company's Phase I/IIa study ...

ACCESS Newswire 3 months ago

SPAGO.ST
-0.46%
7UX.F
Spago Nanomedical Interim Report January-September 2024

LUND, SWEDEN / ACCESSWIRE / November 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Progress for the Tumorad program JULY - SEPTEMBER IN BRIEF Net sales for the quarter amounted to KSEK 485 (KSEK 271) The loss for the quarter amounted to KSEK ...

ACCESS Newswire 5 months ago

7UX.F

SPAGO.ST
-0.46%
Nomination Committee Appointed for Spago Nanomedical’s Annual General Meeting 2025

LUND, SE / ACCESSWIRE / October 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM"), a nomination committee for the 2025 AGM has been ...

ACCESS Newswire 5 months ago

SPAGO.ST
-0.46%
7UX.F
Spago Nanomedical in New Phase with Full Focus on the Tumorad Program

LUND, SWEDEN / ACCESSWIRE / October 1, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Board of Directors of Spago Nanomedical AB (publ) has decided that the company's resources will be focused on the development of Tumorad with the company's ...

ACCESS Newswire 6 months ago

7UX.F

SPAGO.ST
-0.46%
Spago Nanomedical's Phase I/IIa Study Tumorad-01 Continues Following Successful Treatment Completion of First Patient Group

LUND, SE / ACCESSWIRE / August 27, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that the independent Data Monitoring Committee (DMC) recommends to proceed the clinical phase I/IIa study Tumorad-01 ...

ACCESS Newswire 7 months ago

7UX.F

SPAGO.ST
-0.46%
Spago Nanomedical Interim Report January-June 2024

LUND, SE / ACCESSWIRE / August 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Clinical and non-clinical progress in the Tumorad program APRIL - JUNE IN BRIEF Net sales for the quarter amounted to KSEK 459 (KSEK 114) The loss for the quarter ...

ACCESS Newswire 7 months ago

SPAGO.ST
-0.46%
7UX.F
Bulletin from the 2024 Annual General Meeting of Spago Nanomedical AB

LUND, SE / ACCESSWIRE / June 10, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, June 10, 2024, at which the AGM resolved to approve the income statement and balance ...

ACCESS Newswire 10 months ago

7UX.F

SPAGO.ST
-0.46%
Spago Nanomedical Receives Declarations of Intent from the Largest Owner, Board and Management Team Regarding the Exercise of TO12

LUND, SWEDEN / ACCESSWIRE / May 23, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) ("Spago Nanomedical" or the "Company") has received declarations of intent from, among others, the Company's largest owner, Peter Lindell, ...

ACCESS Newswire 10 months ago

7UX.F

SPAGO.ST
-0.46%
Spago Nanomedical Provides an Update on Tumorad-01 - Trial Proceeds as Planned

LUND, SWEDEN / ACCESSWIRE / May 20, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that both of the clinical sites in the phase I/IIa study Tumorad-01 are actively recruiting patients. So far two patients ...

ACCESS Newswire 10 months ago

7UX.F

SPAGO.ST
-0.46%
The Exercise Period for Spago Nanomedical's Warrants of Series TO12 Commences Today

LUND, SE / ACCESSWIRE / May 17, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) ("Spago Nanomedical" or the "Company") issued a total of 127,321,212 warrants of series TO12 ("Warrants") within the framework of a rights ...

ACCESS Newswire 10 months ago

SPAGO.ST
-0.46%
7UX.F
Spago Nanomedical Interim Report January-March 2024

LUND, SWEDEN / ACCESSWIRE / May 2, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Positive start to an important year JANUARY - MARCH IN BRIEF Net sales for the quarter amounted to KSEK 350 (KSEK 88) The loss for the quarter amounted to KSEK -7.763 ...

ACCESS Newswire 11 months ago

SPAGO.ST
-0.46%
7UX.F
Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad

LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer. In the model, 177Lu-SN201 ...

ACCESS Newswire 11 months ago

7UX.F

SPAGO.ST
-0.46%

Performance Overview

Return	SPAGO.ST	OMX Stockholm 30 Index (^OMX)
YTD	+10.71%	-4.45%
1-Year	-28.15%	-4.78%
3-Year	-92.78%	+13.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Spago Nanomedical AB (publ) (SPAGO.ST)

Notice To Annual General Meeting of Spago Nanomedical AB (PUBL)

Nomination Committee's Proposal for a New Chairman and Composition of Spago Nanomedical’s Board

Spago Nanomedical Proceeds with Increased Dose in the Phase I/IIa study Tumorad-01

Spago Nanomedical year-end report January-December, 2024

Spago Nanomedical Article on SPAGOPIX-01 Clinical Results Accepted for Publication in Investigative Radiology

Second Patient Group Successfully Dosed in Spago Nanomedical's Phase I/IIa Study Tumorad-01

Spago Nanomedical Interim Report January-September 2024

Nomination Committee Appointed for Spago Nanomedical’s Annual General Meeting 2025

Spago Nanomedical in New Phase with Full Focus on the Tumorad Program

Spago Nanomedical's Phase I/IIa Study Tumorad-01 Continues Following Successful Treatment Completion of First Patient Group

Spago Nanomedical Interim Report January-June 2024

Bulletin from the 2024 Annual General Meeting of Spago Nanomedical AB

Spago Nanomedical Receives Declarations of Intent from the Largest Owner, Board and Management Team Regarding the Exercise of TO12

Spago Nanomedical Provides an Update on Tumorad-01 - Trial Proceeds as Planned

The Exercise Period for Spago Nanomedical's Warrants of Series TO12 Commences Today

Spago Nanomedical Interim Report January-March 2024

Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad

Performance Overview